Literature DB >> 1947863

Prospective cost allocations for the chronic schizophrenic patient.

S S Sharfstein1.   

Abstract

Schizophrenia affects from 0.5 percent to 1.0 percent of the population and is often a chronic relapsing illness with high morbidity. Because it strikes young adults, the lifetime direct and indirect costs are considerable. One method of budgeting the costs of treatment is through a prospective method with the development of "risk-adjusted" capitation rates that take into account a patient's past use of services, perceived health status, and level of disability. Such a system may provide opportunities to improve the quality of mental health services by increasing service flexibility, particularly in the development and differentiation of outpatient services. The essence of the approach is to encourage early intervention by reducing financial barriers for patients, especially barriers to alternatives to expensive inpatient services. One method currently employed in Rochester, New York, which creates a capitation payment system for the chronically mentally ill, will be described. The implications of this system for public policy will be discussed as we struggle to treat and care for chronic schizophrenic patients in humane and compassionate ways.

Entities:  

Mesh:

Year:  1991        PMID: 1947863     DOI: 10.1093/schbul/17.3.395

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  3 in total

Review 1.  Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

Authors:  K G Terkelsen; A Menikoff
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

2.  The role of private insurance in financing treatment for depression.

Authors:  S S Sharfstein
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-08       Impact factor: 4.328

Review 3.  Health maintenance organizations and persons with severe mental illness.

Authors:  B H McFarland
Journal:  Community Ment Health J       Date:  1994-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.